

Institutional Biosafety Committee - Regular Meeting

Thursday, September 04, 2025

Zoom

Meeting Minutes

VOTING MEMBERS PRESENT:	D. Elsaesser, K. Burns, J. Corcoran, G. Dean, S. Kasper, R. Larson, E. Otten, E. Serafin, T. Rausch, F. Schaefer
VOTING MEMBERS NOT PRESENT:	S. Apewokin, G. Babcock, M. Espinola, J. Yu
AD HOC MEMBERS/CONSULTANTS/GUESTS:	T. Gulley
IBC STAFF:	D. Healy, B. Kesavalu

K. Burns convened the meeting at 12:00 p.m.

- I. **Conflicts of Interest**
- II. **Minutes** - Minutes from the previous IBC meeting (08/07/25) were approved (8: YES/0: NO/2: Abstained)
- III. **Old Business**

IBC Protocol Number	PI	Type of Submission	Biosafety Level	IBC Item
1. 25-07-24-01	Bernstein D	Renewal	BSL2	<i>in vitro</i> : HDM (cell lines)
Status	<ul style="list-style-type: none"> This protocol was voted and approved on 08/07/25 pending modifications. The PI has not completed his BBP training. 			

- IV. **New Business**
 - A. **Primary Protocols** (0 protocols)
 - B. **Secondary Protocols** (10 protocols)

IBC Protocol Number	PI	Type of Submission	Biosafety Level	IBC Items
1. 25-05-23-02	Ulrich-Lai	Amendment	BSL2	<i>in vivo</i> : AAV vector AMENDMENT: <i>in vitro</i>: HDM (brain tissue)
IBC Requests:	<ol style="list-style-type: none"> Lab staff need to complete their BBP training; IBC Form Section II. B - Project #2 - Expand "NDR"; Section II. B - Project #2 - Include if the brain tissue is obtained from individuals with neurological disease and discuss any screening related to prions; Section III. A - Confirm that no other aerosol generating equipment is used to process brain tissue besides pipet; Section III. A - Pipet - Project #2 - If using serological pipets with brain tissue, include aerosol mitigation. Consult the eManual for more information. Form D – Biohazard in Animals: Section I - Update your IACUC protocol number; 			

	7. Section III. C - Check YES for "Additional Information" and indicate what type of sharps will be discarded in the sharps containers.			
Motion	Approve upon modifications addressing outlined issues			
Voting Result & Dual Use	YES: 10	NO: 0	Abstained: 0	Dual Use? No

IBC Protocol Number	PI	Type of Submission	Biosafety Level	IBC Items
2. 25-07-31-01	Zhang Y	Renewal	BSL2	<i>in vitro</i> : Lentiviral vector, <i>Escherichia coli</i> (RG1) <i>in vitro</i> and <i>in vivo</i> : HDM (established and primary cells including virally transduced cells) <i>in vivo</i> : HDM (Patient Derived Xenograft)
IBC Requests:	1. Lab staff need to complete their BBP training; <u>Main Form – General Safety:</u> 2. Section III. B - Additional Information - This protocol is only related to biological safety. Remove information in the first sentence since it relates to chemical safety; 3. Section III. B - Additional Information - Replace "he" with "the". <u>Form A – Recombinant or Synthetic Nucleic Acid:</u> 4. Section I - Gene #1, #2, #9 and #13 - In "Additional Information", indicate how genes are inhibited (e.g. shRNA, siRNA, miRNA, CRISPR/Cas9) . <u>Form D – Biohazard in Animals:</u> 5. Section III. B - Confirm that all cell administration, including intradermal injection, are performed in animals under anesthesia.			
Motion	Approve upon modifications addressing outlined issues			
Voting Result & Dual Use	YES: 10	NO: 0	Abstained: 0	Dual Use? No

IBC Protocol Number	PI	Type of Submission	Biosafety Level	IBC Items
3. 25-08-11-01	McNamara	Renewal	BSL2	<i>in vitro</i> : Blood, plasma, red blood cells, CSF
IBC Requests:	<u>Main Form – General Safety:</u> 1. Section II. B - Expand description to include the importance of fatty acid analysis; 2. Section II. B - Expand "CSF"; 3. Section III. Indicate if additional equipment like a centrifuge, sonicator, etc are used; 4. Section III. C - Whenever working in a lab, closed-toe shoes must be worn. Check the box in this regard.			
Motion	Approve upon modifications addressing outlined issues			
Voting Result & Dual Use	YES: 10	NO: 0	Abstained: 0	Dual Use? No

IBC Protocol Number	PI	Type of Submission	Biosafety Level	IBC Items
4. 25-08-11-02	Fan G	Renewal	BSL2	<i>in vitro</i> : HDM (HEK293 cells), <i>Lactobacillus rhamnosus</i> , <i>Escherichia coli</i> (RG1) <i>in vitro</i> and <i>in vivo</i> : Adenoviral and AAV vectors, murine virally transduced cells
IBC Requests:	<p><u>Main Form – General Safety:</u></p> <ol style="list-style-type: none"> Section II. B - Project #2 - Remove second sentence about LPS; Section III. B - Additional Information - Remove info regarding Ethidium Bromide and Doxorubicin since they are not <u>biological</u> hazards; Section III. B - Check "yes" for additional info and include what type of sharps will be discarded in the sharps containers. <p><u>Form A – Recombinant or Synthetic Nucleic Acid:</u></p> <ol style="list-style-type: none"> Include GFP in Section I and Section II. B – system #2. <p><u>Form C – Human & Non-Human Primate (NHP) Derived Materials</u></p> <ol style="list-style-type: none"> Section I – Table - Indicate source of HEK cells. <p><u>Form D – Biohazard in Animals:</u></p> <ol style="list-style-type: none"> Section I - Update IACUC protocol number; Section III. B - Especially while using sharps, there is always a risk for exposure. Remove last sentence and describe the potential risk of exposure and shedding of virus after injecting viral vectors into mice; Section III. C - Check "yes" for additional info and include what type of sharps will be discarded in the sharps containers. 			
Motion	Approve upon modifications addressing outlined issues			
Voting Result & Dual Use	YES: 10	NO: 0	Abstained: 0	Dual Use? No

IBC Protocol Number	PI	Type of Submission	Biosafety Level	IBC Items
5. 25-08-11-03	Mast	Renewal	BSL2	<i>in vitro</i> : HDM (hepatic tissue, hepatic tumor)
IBC Requests:	<p><u>Main Form – General Safety:</u></p> <ol style="list-style-type: none"> Section I.B - Indicate N/A for office and lab phone if there are none; Section II. B - Confirm that the first sentence is accurate; Section II. B - Remove 2nd (funding not needed), 4th, and 5th paragraphs since this info is in Form C, section II.A; Section II. B - Last paragraph - Include "UC Biosafety Office" as a guideline provider; Section III. A - Verify if pipets, centrifuges, homogenizers, sonicators, etc are not used; Section III. B – Additional Information – Specify what sharps are discarded into sharps containers; Section III. C - Whenever working in a lab, closed-toe shoes must be worn. Check the box in this regard. <p><u>Form C – Human & Non-Human Primate (NHP) Derived Materials</u></p> <ol style="list-style-type: none"> Section I – Table - Is liver tissue screened for hepatitis viruses? 			
Motion	Approve upon modifications addressing outlined issues			
Voting Result & Dual Use	YES: 10	NO: 0	Abstained: 0	Dual Use? No

IBC Protocol Number	PI	Type of Submission	Biosafety Level	IBC Items
6. 25-08-12-01	Pritts	Renewal	BSL2	<u><i>in vitro</i></u> : HDM (cell line: HUVEC and blood)
IBC Requests:	Main Form – General Safety: <ol style="list-style-type: none"> Section I. B - Enter "N/A" for "office phone"; Section II. B - Second paragraph - "Negative affects" should read "negative effects"; Section III. A - Pipet - Instead of referring to the eManual, list the mitigation within the manual that is adopted in the lab. 			
Motion	Approve upon modifications addressing outlined issues			
Voting Result & Dual Use	YES: 10	NO: 0	Abstained: 0	Dual Use? No

IBC Protocol Number	PI	Type of Submission	Biosafety Level	IBC Items
7. 25-08-12-02	Baccei	Renewal	BSL2	<u><i>in vivo</i></u> : AAV vector
IBC Requests:	Main Form – General Safety: <ol style="list-style-type: none"> Section III - Confirm that vortex, homogenizer, sonicator, etc are not used and pipet are the only aerosol generating equipment used with AAV. 			
Motion	Approve upon modifications addressing outlined issues			
Voting Result & Dual Use	YES: 9 <i>E. Serafin did not vote (conflicted)</i>	NO: 0	Abstained: 0	Dual Use? No

IBC Protocol Number	PI	Type of Submission	Biosafety Level	IBC Items
8. 25-08-12-03	Patra	Renewal	BSL2	<u><i>in vitro</i></u> : Retroviral vector, <i>Escherichia coli</i> (RG1), and HDM (blood, tissues) <u><i>in vivo</i></u> : AAV vector <u><i>in vitro</i></u> and <u><i>in vivo</i></u> : Adenoviral and Lentiviral vector, and HDM (primary and established cell lines including virally transduced cells)

IBC Requests:	<p><u>Main Form – General Safety:</u></p> <ol style="list-style-type: none"> Section I. B - If secondary contact does not have an office phone number, enter "N/A". <p><u>Form A – Recombinant or Synthetic Nucleic Acid:</u></p> <ol style="list-style-type: none"> Section I - Genes #1 to #5 - Check YES for "Additional Information" and indicate how genes are inhibited (e.g. shRNA, siRNA, miRNA, CRISPR/Cas9); Section I - Gene #2 - Check YES for "Additional Information" and indicate what is the "other" gene source of tumor suppressors; Section I - Gene #7 - Luciferase is expressed by lentiviral vector system #3 in vector table. Add Luciferase here with gene source arthropod. <p><u>Form C – Human & Non-Human Primate (NHP) Derived Materials</u></p> <ol style="list-style-type: none"> Section I - Table - Remove references to murine cells. <p><u>Form D – Biohazard in Animals:</u></p> <ol style="list-style-type: none"> Section II - Provide the animal species receiving viral vectors; Section III. A - Discuss the potential of viral vector shedding; Section III. B - Confirm that all animal procedures, including subcutaneous injection of cells, are performed in animals under anesthesia; Section III. C - Additional Information - Remove information about Tamoxifen since IBC does not oversee chemical safety. 			
Motion	Approve upon modifications addressing outlined issues			
Voting Result & Dual Use	YES: 10	NO: 0	Abstained: 0	Dual Use? No

IBC Protocol Number	PI	Type of Submission	Biosafety Level	IBC Items
9. 25-08-15-01	Huaman	Renewal	BSL2	<p><i>in vitro</i>: HDM (primary cells, blood, tissues, bodily fluids from patients with infectious diseases including COVID-19 and Monkeypox) - Core facility</p> <p><i>in vitro</i> and <i>in vivo</i>: Mycobacterium bovis (BCG) and Mycobacterium tuberculosis (H37Ra)</p>
IBC Requests:	<p><u>Main Form – General Safety:</u></p> <ol style="list-style-type: none"> Section I. D - Remove "other" from the list since the non-UC facilities field was already completed; Section II. C - Note that the safety guards for COVID-19 patient derived materials have been relaxed and no longer requires enhanced BSL2 practices. Select the " BSL2" box instead. <p><u>Form D – Biohazard in Animals:</u></p> <ol style="list-style-type: none"> Section II - Confirm the use of a satellite location for <i>in vivo</i> project involving bacteria. If that is correct, indicate what is performed in that location and how animals are transferred to LAMS housing; Section III. B - Confirm that anesthesia is also used for IP injection of bacteria. 			
Motion	Approve upon modifications addressing outlined issues			
Voting Result & Dual Use	YES: 10	NO: 0	Abstained: 0	Dual Use? No

IBC Protocol Number	PI	Type of Submission	Biosafety Level	IBC Items
10. 25-08-20-01	Hong	Renewal	BSL2	<i>in vitro</i> : Lentiviral vector, <i>Neurospora crassa</i> , <i>Saccharomyces cerevisiae</i> , <i>Escherichia coli</i> (RG1) <i>in vitro</i> and <i>in vivo</i> : HDM (cell lines and organoids)
IBC Requests:	<p>Main Form – General Safety:</p> <ol style="list-style-type: none"> Section I. B - If secondary contact does not have an office phone number, enter "N/A" ; Section I. D - Confirm that all locations are shared with another PI; Section II. B - 4th paragraph - Indicate that the viral vector core used is from CCHMC; Section II. B - 5th paragraph - For clarity, mention that this IBC protocol also covers the activities of the Live Microscopy facility; Section III. A - Is BSC or fume hood used while using sonicator? Section III. B - In "Additional Information", list the types of sharps that are disposed of in the sharps containers; <p>Form A – Recombinant or Synthetic Nucleic Acid:</p> <ol style="list-style-type: none"> Section I - Gene #10 - Include in "Additional Information" that the "other" gene source corresponds to "sea coral"; Section I - Gene #13 - Include in "Additional Information" that the "other" gene source is synthetic. <p>Form B -Microbial/Infectious Agents</p> <ol style="list-style-type: none"> Provide the strain for <i>S. cerevisiae</i>. <p>Form C – Human & Non-Human Primate (NHP) Derived Materials</p> <ol style="list-style-type: none"> Section I - Table -_Organoids - Change “biosy” to “biopsy”; <p>Form D – Biohazard in Animals:</p> <ol style="list-style-type: none"> Section III. C - Since you there is a statement about the use of 1 ml syringe, check the box for "sharps containers" to reflect proper disposal. 			
Motion	Approve upon modifications addressing outlined issues			
Voting Result & Dual Use	YES: 10	NO: 0	Abstained: 0	Dual Use? No

V. Protocol Updates (August 1st to August 28th) - 9 protocols

- IBC# 23-06-12-01 - PI: Oria - Personnel
- IBC# 25-03-19-01 - PI: Owens - Personnel, Location
- IBC# 24-06-18-02 - PI: Byrd - Personnel
- IBC# 23-03-16-01 - PI: Shi - Personnel
- IBC# 25-05-06-01 - PI: Madala - Personnel
- IBC# 24-08-21-02 - PI: Wasylishen - Location
- IBC# 24-01-20-02 - PI: Scaglioni- Personnel
- IBC# 24-03-06-01 - PI: Luo - Amendment, *in vivo* hPSC
- IBC# 25-07-03-01 - PI: Natarajan - Personnel

VI. Reports

- IBC/ BSO of (B. Kesavalu)
Lab inspection reports are transitioning into REDCap.

VII. Educational Materials/Updates

- [UNIDIR Unveils Strategy to Bolster Biosecurity Awareness Among Scientists](#) Global Biodefense, August 2025

B. **New Study Reveals Striking Differences in Disease Severity Between Two Hendra Virus Genotypes**

Global Biodefense, August 2025

K. Burns adjourned the meeting at 12:24 p.m.

